US 11,952,369 B2
Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease
Olivier Schueller, Cambridge, MA (US); and Jeegar P. Patel, Hillsborough, NJ (US)
Assigned to Kadmon Corporation, LLC, Bridgewater, NJ (US)
Filed by Kadmon Corporation, LLC, Bridgewater, NJ (US)
Filed on Feb. 3, 2023, as Appl. No. 18/105,427.
Application 18/105,427 is a continuation of application No. PCT/US2022/037210, filed on Jul. 14, 2022.
Prior Publication US 2024/0025881 A1, Jan. 25, 2024
Int. Cl. C07D 403/12 (2006.01); A61K 47/54 (2017.01)
CPC C07D 403/12 (2013.01) [A61K 47/549 (2017.08)] 2 Claims
 
1. An isolated or synthesized belumosudil glucuronide or O-dealkylated belumosudil sulfate, or a pharmaceutically acceptable salt thereof.